Principal Financial Group Inc Immunovant, Inc. Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

A detailed history of Principal Financial Group Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 951,124 shares of IMVT stock, worth $26.2 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

951,124

Previous 559,688 69.94%

Holding current value

$26.2 Million

Previous $14.8 Million 77.09%

% of portfolio

0.02%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	BUY	$27.51 - $27.51 $10.8 Million - $10.8 Million	391,436 Added 69.94%	951,124 $26.2 Million
Q2 2024 Jul 29, 2024	SELL	$25.1 - $31.61 $578,128 - $728,073	-23,033 Reduced 3.95%	559,688 $14.8 Million
Q1 2024 Apr 29, 2024	BUY	$30.27 - $43.79 $4.32 Million - $6.24 Million	142,606 Added 32.4%	582,721 $18.8 Million
Q4 2023 Feb 07, 2024	BUY	$31.31 - $44.19 $3.54 Million - $5 Million	113,040 Added 34.56%	440,115 $18.5 Million
Q3 2023 Nov 02, 2023	BUY	$18.55 - $39.96 $5.63 Million - $12.1 Million	303,707 Added 1299.67%	327,075 $12.6 Million
Q2 2023 Aug 07, 2023	SELL	$14.2 - $23.75 $9,712 - $16,245	-684 Reduced 2.84%	23,368 $443,000
Q1 2023 May 09, 2023	BUY	$15.27 - $19.72 $20,141 - $26,010	1,319 Added 5.8%	24,052 $373,000
Q4 2022 Feb 09, 2023	BUY	$6.59 - $17.75 $32,264 - $86,904	4,896 Added 27.45%	22,733 $403,000
Q3 2022 Nov 09, 2022	BUY	$3.93 - $6.37 $9,864 - $15,988	2,510 Added 16.38%	17,837 $99,000
Q2 2022 Aug 10, 2022	BUY	$3.38 - $5.65 $7,750 - $12,955	2,293 Added 17.59%	15,327 $60,000
Q1 2022 May 09, 2022	SELL	$5.06 - $8.77 $3,714 - $6,437	-734 Reduced 5.33%	13,034 $72,000
Q4 2021 Feb 09, 2022	SELL	$7.33 - $9.32 $41,737 - $53,068	-5,694 Reduced 29.26%	13,768 $117,000
Q3 2021 Nov 09, 2021	SELL	$7.01 - $11.37 $22,116 - $35,872	-3,155 Reduced 13.95%	19,462 $169,000
Q2 2021 Aug 10, 2021	BUY	$9.4 - $16.85 $29,083 - $52,133	3,094 Added 15.85%	22,617 $239,000
Q1 2021 May 10, 2021	SELL	$13.08 - $49.6 $106,222 - $402,801	-8,121 Reduced 29.38%	19,523 $313,000
Q4 2020 Feb 08, 2021	BUY	$36.36 - $52.71 $1.01 Million - $1.46 Million	27,644 New	27,644 $1.28 Million

Others Institutions Holding IMVT

# of Institutions

211

Shares Held

66.9M

Call Options Held

2.3M

Put Options Held

631K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Immunovant, Inc. Transaction History